R&D The UK can’t just be a life sciences lab – we need manufactu... Rachel Reeves is right: the UK is at the forefront of life sciences, with some world-leading research and innovation.
Market Access Life sciences real estate is booming amid looming ‘patent cl... The life sciences sector across Europe has remained remarkably resilient in recent years, with record levels of growth and investment.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
